These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38986909)

  • 1. Therapeutic liposomal combination to enhance chemotherapy response and immune activation of tumor microenvironment.
    Gu Z; Yin J; Da Silva CG; Liu Q; Cruz LJ; Ossendorp F; Snaar-Jagalska E
    J Control Release; 2024 Sep; 373():38-54. PubMed ID: 38986909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TLR 7/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages.
    Liu Z; Xie Y; Xiong Y; Liu S; Qiu C; Zhu Z; Mao H; Yu M; Wang X
    Cancer Lett; 2020 Jan; 469():173-185. PubMed ID: 31629935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resiquimod-loaded cationic liposomes cure mice with peritoneal carcinomatosis and induce specific anti-tumor immunity.
    Chao PH; Chan V; Wu J; Andrew LJ; Li SD
    J Control Release; 2024 Aug; 372():362-371. PubMed ID: 38909698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor microenvironment-responsive macrophage-mediated immunotherapeutic drug delivery.
    Zhang X; Yue L; Cao L; Liu K; Yang S; Liang S; Liu L; Zhao C; Wu D; Wang Z; Tian R; Rao L
    Acta Biomater; 2024 Sep; 186():369-382. PubMed ID: 39097127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing anti-tumor immunity through liposomal oxaliplatin and localized immunotherapy via STING activation.
    Gu Z; Hao Y; Schomann T; Ossendorp F; Ten Dijke P; Cruz LJ
    J Control Release; 2023 May; 357():531-544. PubMed ID: 37030544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of antitumor immunity contributes to the enhanced therapeutic efficacy of liposomal oxaliplatin in mouse model.
    Shimizu T; Abu Lila AS; Nishio M; Doi Y; Ando H; Ukawa M; Ishima Y; Ishida T
    Cancer Sci; 2017 Sep; 108(9):1864-1869. PubMed ID: 28643902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted co-delivery of rapamycin and oxaliplatin by liposomes suppresses tumor growth and metastasis of colorectal cancer.
    Yu H; Liu S; Yuan Z; Huang H; Yan P; Zhu W
    Biomed Pharmacother; 2024 Sep; 178():117192. PubMed ID: 39098178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developing oxaliplatin and IL-15 Co-carried gels as drug depots to enable triple-interlocked combination therapy for colorectal cancer.
    Jiang D; Nie H; Wang Z; Xiong Y; Shen H; Gao Y; Zhu X; Mao Z
    Colloids Surf B Biointerfaces; 2024 Sep; 241():113996. PubMed ID: 38850745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune modulation of the liver metastatic colorectal cancer microenvironment via the oral CAPOX-mediated cGAS-STING pathway.
    Park SJ; Kweon S; Moyo MK; Kim HR; Choi JU; Lee NK; Maharjan R; Cho YS; Park JW; Byun Y
    Biomaterials; 2024 Oct; 310():122625. PubMed ID: 38820768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells.
    Fang H; Ang B; Xu X; Huang X; Wu Y; Sun Y; Wang W; Li N; Cao X; Wan T
    Cell Mol Immunol; 2014 Mar; 11(2):150-9. PubMed ID: 24362470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-activation with TLR7 in combination with thioridazine and loratadine promotes tumoricidal T-cell activity in colorectal cancer.
    Lin X; Zhang J; Wang X; Lin G; Chen T
    Anticancer Drugs; 2020 Nov; 31(10):989-996. PubMed ID: 32694422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Remodeling the hepatic immune microenvironment and demolishing T cell traps to enhance immunotherapy efficacy in liver metastasis.
    Luo Z; Jiang M; Cheng N; Zhao X; Liu H; Wang S; Lin Q; Huang J; Guo X; Liu X; Shan X; Lu Y; Shi Y; Luo L; You J
    J Control Release; 2024 Sep; 373():890-904. PubMed ID: 39067794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Large, Anionic Liposomes Enable Targeted Intraperitoneal Delivery of a TLR 7/8 Agonist To Repolarize Ovarian Tumors' Microenvironment.
    Kang Y; Flores L; Ngai HW; Cornejo YR; Haber T; McDonald M; Moreira DF; Gonzaga JM; Abidi W; Zhang Y; Hammad M; Kortylewski M; Aboody KS; Berlin JM
    Bioconjug Chem; 2021 Aug; 32(8):1581-1592. PubMed ID: 34289694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trifluridine/Tipiracil plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages.
    Limagne E; Thibaudin M; Nuttin L; Spill A; Derangère V; Fumet JD; Amellal N; Peranzoni E; Cattan V; Ghiringhelli F
    Cancer Immunol Res; 2019 Dec; 7(12):1958-1969. PubMed ID: 31611243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and evaluation of oxaliplatin and irinotecan co-loaded liposomes for enhanced colorectal cancer therapy.
    Zhang B; Wang T; Yang S; Xiao Y; Song Y; Zhang N; Garg S
    J Control Release; 2016 Sep; 238():10-21. PubMed ID: 27432750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor RNA-loaded nanoliposomes increases the anti-tumor immune response in colorectal cancer.
    Dai D; Yin Y; Hu Y; Lu Y; Zou H; Lu G; Wang Q; Lian J; Gao J; Shen X
    Drug Deliv; 2021 Dec; 28(1):1548-1561. PubMed ID: 34286631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy.
    Zhu H; Shan Y; Ge K; Lu J; Kong W; Jia C
    Cell Oncol (Dordr); 2020 Dec; 43(6):1203-1214. PubMed ID: 32797385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomal oxaliplatin prodrugs loaded with metformin potentiate immunotherapy for colorectal cancer.
    Song L; Hao Y; Wang C; Han Y; Zhu Y; Feng L; Miao L; Liu Z
    J Control Release; 2022 Oct; 350():922-932. PubMed ID: 36108810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Elucidation for Intratumor Localization of a DDS-based Anticancer Drug and Enhancement of Its Therapeutic Effects via Improvement of the Tumor Microenvironment].
    Ando H
    Yakugaku Zasshi; 2021; 141(11):1241-1245. PubMed ID: 34719544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy of metronomic S-1 dosing with oxaliplatin-containing polyethylene glycol-coated liposome improves antitumor activity in a murine colorectal tumor model.
    Doi Y; Okada T; Matsumoto H; Ichihara M; Ishida T; Kiwada H
    Cancer Sci; 2010 Nov; 101(11):2470-5. PubMed ID: 20731663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.